
FDA greenlights two options for shielding infants from RSV in the U.S. Pregnant individuals can now receive the first RSV vaccine, transferring immunity to newborns. The FDA also approves Beyfortus (nirsevimab), an antibody treatment. RSV, causing severe infant respiratory illness, leads to 58,000-80,000 annual hospitalizations. CDC recommends Beyfortus for infants under 8 months and high-risk 8 to 19 months olds.
Like
Save
Share